Last updated on July 2019

Study of the Safety Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis


Brief description of study

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

Detailed Study Description

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD. Eligible subjects will be enrolled and randomized to treatment with BTX 1204 or Vehicle for 84 days. Approximately two hundred (200) subjects will be enrolled. Subjects will receive BID application of study drug for 84 days with a final application on the evening of Day 84 for a total of 168 doses.

Clinical Study Identifier: NCT03824405

Find a site near you

Start Over

Precision Clinical Research

Davie, FL United States
0.68miles
  Connect »